Skip to main content
. 2022 Apr 13;15(1):30–38. doi: 10.1111/jebm.12465

TABLE 2.

Persistent symptoms

Total QJYQ group Control group
Variables (n = 388) (n = 194) (= 194) p Value
Breathlessness 115 (29.64) 61 (31.44) 54 (27.84) 0.436
Fatigue 115 (29.64) 59 (30.41) 56 (28.87) 0.739
Chest distress 94 (24.23) 46 (23.71) 48 (24.74) 0.813
Cough 71 (18.30) 35 (18.04) 36 (18.56) 0.896
Insomnia 70 (18.04) 36 (18.56) 34 (17.53) 0.792
Pharynx ministry unwell 56 (14.43) 27 (13.92) 29 (14.95) 0.773
Expectoration 48 (12.37) 27 (13.92) 21 (10.82) 0.355
Hair loss 30 (7.73) 17 (8.76) 13 (6.70) 0.447
Palpitation 18 (4.64) 10 (5.15) 8 (4.12) 0.629
Constipation 17 (4.38) 9 (4.64) 8 (4.12) 0.804
Decreased appetite 16 (4.12) 8 (4.12) 8 (4.12) 1
Dizziness 12 (3.09) 6 (3.09) 6 (3.09) 1
Hidrosis 12 (3.09) 7 (3.61) 5 (2.58) 0.558
Body pain 9 (2.32) 6 (3.09) 3 (1.55) 0.312
Dysphoria 8 (2.06) 3 (1.55) 5 (2.58) 0.475
Headache 8 (2.06) 5 (2.58) 3 (1.55) 0.475
Smell disorder 8 (2.06) 6 (3.09) 2 (1.03) 0.153
Diarrhea 7 (1.80) 5 (2.58) 2 (1.03) 0.253
Taste disorder 4 (1.03) 3 (1.55) 1 (0.52) 0.315
Chest pain 3 (0.77) 2 (1.03) 1 (0.52) 0.562

Note: Data are n (%).

QJYQ = Qingjin Yiqi granules.